Abstract
Human transferrin receptor 1 (TfR1) is expressed on malignant cells at levels several fold higher than those on normal cells and its expression can be correlated with tumor stage or cancer progression. It is a potentially rational target for drug delivery. To identify novel ligands which can recognize the TfR1 specifically, a random phage displayed 12-mer peptide library was screened and two consensus motifs of the peptides which are displayed by the positive phages RXR and RXXXR (x is any amino acid) were yield. The phage displaying peptide SPRPRHTLRLSL (designated as B18) exhibited the highest affinity to TfR1 in phage ELISA and B18 could bind to TfR1 specifically in a dose dependent manner. The flow cytometry assay and immunocellularchemistry assay showed that the B18 could bind to TfR1 positive carcinoma cells with specificity. In addition, the biodistribution assay indicated that B18 could home to TfR1 positive tumor tissue specifically. Our study suggests that the peptide exhibited by B18 is a potentially promising targeting peptide for tumor diagnosis and treatment.
Keywords: TfR1, phage display, peptide, malignant cells, normal cells, tumor, cancer progression, flow cytometry assay
Protein & Peptide Letters
Title:Identification of a Novel Peptide Ligand of Human Transfrrin Receptor 1 for Targeted Tumor Delivery Drug
Volume: 20 Issue: 1
Author(s): Qin Xin, Zhang Cun, Xue Xiaochang, Li Meng, Li Weina, Hao Qiang, Zhang Yingqi, Yan Zhen and Zhang Wei
Affiliation:
Keywords: TfR1, phage display, peptide, malignant cells, normal cells, tumor, cancer progression, flow cytometry assay
Abstract: Human transferrin receptor 1 (TfR1) is expressed on malignant cells at levels several fold higher than those on normal cells and its expression can be correlated with tumor stage or cancer progression. It is a potentially rational target for drug delivery. To identify novel ligands which can recognize the TfR1 specifically, a random phage displayed 12-mer peptide library was screened and two consensus motifs of the peptides which are displayed by the positive phages RXR and RXXXR (x is any amino acid) were yield. The phage displaying peptide SPRPRHTLRLSL (designated as B18) exhibited the highest affinity to TfR1 in phage ELISA and B18 could bind to TfR1 specifically in a dose dependent manner. The flow cytometry assay and immunocellularchemistry assay showed that the B18 could bind to TfR1 positive carcinoma cells with specificity. In addition, the biodistribution assay indicated that B18 could home to TfR1 positive tumor tissue specifically. Our study suggests that the peptide exhibited by B18 is a potentially promising targeting peptide for tumor diagnosis and treatment.
Export Options
About this article
Cite this article as:
Xin Qin, Cun Zhang, Xiaochang Xue, Meng Li, Weina Li, Qiang Hao, Yingqi Zhang, Zhen Yan and Wei Zhang, Identification of a Novel Peptide Ligand of Human Transfrrin Receptor 1 for Targeted Tumor Delivery Drug, Protein & Peptide Letters 2013; 20 (1) . https://dx.doi.org/10.2174/0929866511307010096
DOI https://dx.doi.org/10.2174/0929866511307010096 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Guanosine Derivatives as Anti-HCV NS5b Polymerase: A QSAR and Molecular Docking Study
Medicinal Chemistry Hepatic Stellate Cell: A Potential Target for Hepatocellular Carcinoma
Current Molecular Pharmacology Polymers Based on Phenyl Boric Acid in Tumor-Targeted Therapy
Anti-Cancer Agents in Medicinal Chemistry Clinical Significance of Thiopurine S-Methyltransferase Gene Polymorphisms
Current Pharmacogenomics Flavonoids in Human Health: From Structure to Biological Activity
Current Nutrition & Food Science Targeting the Acute Myeloid Leukemia Stem Cells
Anti-Cancer Agents in Medicinal Chemistry Cell-penetrating Peptide-mediated Nanovaccine Delivery
Current Drug Targets Sporadic Porphyria in a Patient with Stage II Melanoma Treated with Interferon α
Current Drug Safety The Role of Anaphylatoxins C3a and C5a in Regulating Innate and Adaptive Immune Responses
Inflammation & Allergy - Drug Targets (Discontinued) Structure-Function Relationships and Clinical Applications of L-Asparaginases
Current Medicinal Chemistry Perspectives in Nanomedicine-Based Research Towards Cancer Therapies
Current Nanoscience Advancements in Non-steroidal Antiandrogens as Potential Therapeutic Agents for the Treatment of Prostate Cancer
Mini-Reviews in Medicinal Chemistry De Novo DNMTs and DNA Methylation: Novel Insights into Disease Pathogenesis and Therapy from Epigenomics
Current Pharmaceutical Design A Novel Method for Screening of Anti-Cancer Drugs: Availability of Screening in Acidic Medium
Recent Patents on Biomedical Engineering (Discontinued) Withdrawal Notice: Role of MicroRNAs (224 and 96) as Novel Biomarkers for Hepatocellular Carcinoma
Current Cancer Therapy Reviews New Molecular Targets of Anticancer Therapy – Current Status and Perspectives
Current Medicinal Chemistry Biological Predictors of Aging and Potential of FTIR to Study Age-related Diseases and Aging Metabolic Fingerprint
Current Metabolomics Tetrapyrrolic Macrocycles: Potentialities in Medical Imaging Technologies
Current Organic Synthesis A Concise Review of Current Radiopharmaceuticals in Tumor Angiogenesis Imaging
Current Pharmaceutical Design Melanoma Immunotherapy: Past, Present, and Future
Current Pharmaceutical Design